Answers are grounded in this paper and cite their sources.
The European Medicines Agency (EMEA) is the regulatory body that provides the institutions of the European Community with the best possible scientific advice on the quality, safety and efficacy of medicinal products. Drugs approved by the EMEA are automatically marketable in all the European member states. Since the beginning of the EMEA's activities a number of drugs acting on the central nervous system obtained marketing authorisation. This editorial highlights some aspects of the EMEA rules that may negatively affect the evaluation of medicines for psychiatric disorders.
No takes yet. Share an insight, caveat, or question.
Barbui et al. (2007) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: